Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW (2020) Heart Disease and Stroke Statistics-2020 Update: a report from the American Heart Association. Circulation 141:e139–e596

Article  PubMed  Google Scholar 

Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. (2024) Global epidemiology of heart failure. Nat Rev Cardiol 21(10):717–734. https://doi.org/10.1038/s41569-024-01046-6

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79:e263–e421

Article  PubMed  Google Scholar 

Bassi NS, Ziaeian B, Yancy CW, Fonarow GC (2020) Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol 5:948–951

Article  PubMed  Google Scholar 

Greene SJ, Ayodele I, Pierce JB, Khan MS, Lewsey SC, Yancy CW, Alhanti B, Van Spall HGC, Allen LA, Fonarow GC (2024) Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure. JACC Heart Fail 12(8):1365–1377. https://doi.org/10.1016/j.jchf.2024.03.001

Greene SJ, Butler J, Fonarow GC (2021) Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed. JAMA Cardiol 6:743–744

Article  PubMed  Google Scholar 

Brownell NK, Ziaeian B, Fonarow GC (2021) The gap to fill: rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction. Card Fail Rev 26(7):e18. https://doi.org/10.15420/cfr.2021.18

Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, Zieroth S, Butler J (2022) Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci 7:504–517

Article  PubMed  PubMed Central  Google Scholar 

Greene SJ, Fonarow GC (2021) Clinical inertia and medical therapy for heart failure: the unintended harms of ‘first, do no harm.’ Eur J Heart Fail 23:1343–1345

Article  PubMed  Google Scholar 

Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Rydén L (2001) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Arch Intern Med 161:165–171

Article  CAS  PubMed  Google Scholar 

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet 374:1840–1848

Article  CAS  Google Scholar 

Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators Circulation 94:2807–2816

Article  CAS  PubMed  Google Scholar 

Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938–1952

Article  CAS  PubMed  Google Scholar 

Biegus J, Mebazaa A, Davison B, Cotter G, Edwards C, Čelutkienė J, Chioncel O, Cohen-Solal A, Filippatos G, Novosadova M, Sliwa K, Adamo M, Arrigo M, Lam CSP, Ter Maaten JM, Deniau B, Barros M, Čerlinskaitė-Bajorė K, Damasceno A, Diaz R, Gayat E, Kimmoun A, Pang PS, Pagnesi M, Saidu H, Takagi K, Tomasoni D, Voors AA, Metra M, Ponikowski P (2024) Effects of rapid uptitration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF. J Am Coll Cardiol 84:323–336

Article  CAS  PubMed  Google Scholar 

Mebazaa A, Davison BA, Biegus J, Edwards C, Murtagh G, Varounis C, Hayrapetyan H, Sisakian H, Ter-Grigoryan VR, Takagi K, Novosadova M, Ponikowski P, Cotter G (2024) Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study. Eur J Heart Fail 26:1507–1517

Article  CAS  PubMed  Google Scholar 

Siddiqi TJ, Cherney D, Siddiqui HF, Jafar TH, Januzzi JL, Khan MS, Levin A, Marx N, Rangaswami J, Testani J, Usman MS, Wanner C, Zannad F, Butler J (2024) Effects of sodium-glucose cotransporter-2 inhibitors on kidney outcomes across baseline cardiovascular-kidney-metabolic conditions: A systematic review and meta-nalyses. J Am Soc Nephrol. https://doi.org/10.1681/ASN.0000000000000491

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229

Article  CAS  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44:3627–3639

Article  CAS  PubMed  Google Scholar 

Shahid I, Fonarow GC, Greene SJ (2023) Time to quadruple guideline-directed medical therapy as a key performance measure for heart failure. J Card Fail 29:730–733

Article  PubMed  Google Scholar 

Carnicelli AP, Li Z, Greiner MA, Lippmann SJ, Greene SJ, Mentz RJ, Hardy NC, Blumer V, Shen X, Yancy CW, Peterson PN, Allen LA, Fonarow GC, O’Brien EC (2021) Sacubitril/valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction. JACC Heart Fail 9:876–886

Article  PubMed  Google Scholar 

Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC (2013) Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 165:979-986.e1

Article  CAS  PubMed  Google Scholar 

Sukumar S, Orkaby AR, Schwartz JB, Marcum Z, Januzzi JL, Vaduganathan M, Warraich HJ (2022) Polypharmacy in older heart failure patients: a multidisciplinary approach. Curr Heart Fail Rep 19:290–302

Article  CAS  PubMed  Google Scholar 

Greene SJ, Butler J, Fonarow GC (2024) Rapid and intensive guideline-directed medical therapy for heart failure: 5 core principles. Circulation 150:422–424

Article  PubMed  Google Scholar 

Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL, Yancy CW (2023) 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 81:1835–1878

Article  PubMed  Google Scholar 

Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD (2021) Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved Trial. Circulation 144:1284–1294

Article  PubMed  PubMed Central  Google Scholar 

Peikert A, Goyal P, Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Vardeny O, Kosiborod MN, Desai AS, Jhund PS, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD (2023) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status. JACC Heart Fail 11:1380–1393

Article  CAS  PubMed  Google Scholar 

Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400:757–767

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P, F-H Committees Investigators (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475–1485

Article  CAS  PubMed  Google Scholar 

Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJ, Solomon SD (2024) Time to significant benefit of finerenone in patients with heart failure. J Am Coll Cardiol. 26:S0735-1097(24)08512-7. https://doi.org/10.1016/j.jacc.2024.09.018

Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Desai AS, Jhund PS, Henderson AD, Brinker M, Lay-Flurrie J, Viswanathan P, Scheerer MF, Lage A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD (2024) Effects of the non-steroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.124.072055

Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Matsumoto S, Merkely B, Zieroth S, Yilmaz MB, Lay-Flurrie J, Viswanathan P, Horvat-Broecker A, Scalise A, McMurray JJV, Solomon SD (2025) Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiol 10(1):42–48. https://doi.org/10.1001/jamacardio.2024.4539

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:34–42

Article  CAS